Dr. David Aboulafia, MD
Claim this profileVirginia Mason Medical Center
Studies Cancer
Studies Soft Tissue Sarcoma
12 reported clinical trials
27 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
CD20 positive
2Soft Tissue Sarcoma
Affiliated Hospitals
Clinical Trials David Aboulafia, MD is currently running
Smoking Cessation Intervention
for HIV/AIDS
This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help patients with HIV quit smoking.
Recruiting1 award N/A8 criteria
Combination Chemotherapy
for Diffuse Large B-Cell Lymphoma
This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (HIV)-positive stage II-IV diffuse large B-cell lymphomas. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride may work better in treating patients with HIV-positive diffuse large B-cell lymphomas.
Recruiting1 award Phase 1
More about David Aboulafia, MD
Clinical Trial Related9 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments David Aboulafia, MD has experience with
- Laboratory Biomarker Analysis
- Fluorouracil
- Imiquimod
- Etoposide
- Cyclophosphamide
- Ibrutinib
Breakdown of trials David Aboulafia, MD has run
Cancer
Soft Tissue Sarcoma
Kaposi's Sarcoma
Kaposi Sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Aboulafia, MD specialize in?
David Aboulafia, MD focuses on Cancer and Soft Tissue Sarcoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is David Aboulafia, MD currently recruiting for clinical trials?
Yes, David Aboulafia, MD is currently recruiting for 3 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that David Aboulafia, MD has studied deeply?
Yes, David Aboulafia, MD has studied treatments such as Laboratory Biomarker Analysis, Fluorouracil, Imiquimod.
What is the best way to schedule an appointment with David Aboulafia, MD?
Apply for one of the trials that David Aboulafia, MD is conducting.
What is the office address of David Aboulafia, MD?
The office of David Aboulafia, MD is located at: Virginia Mason Medical Center, Seattle, Washington 98101 United States. This is the address for their practice at the Virginia Mason Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.